5:53 PM
 | 
Sep 23, 2013
 |  BC Extra  |  Top Story

Ablynx, AbbVie in inflammatory deal

Ablynx N.V. (Euronext:ABLX) climbed EUR 0.85 (11%) to EUR 8.27 on Monday after it and AbbVie Inc. (NYSE:ABBV) partnered to develop ALX-0061 to treat inflammatory diseases. Ablynx will be responsible for completing Phase II development of ALX-0061 in rheumatoid arthritis (RA) and systemic...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >